Literature DB >> 2406341

Leukocyte specificity and binding of human neutrophil attractant/activation protein-1.

E J Leonard1, A Skeel, T Yoshimura, K Noer, S Kutvirt, D Van Epps.   

Abstract

Neutrophil attractant/activation protein-1 (NAP-1) was previously shown to attract human neutrophils, but not monocytes. The purpose of this study was to determine if NAP-1 interacted with other types of blood leukocytes. In addition to its chemotactic activity for neutrophils, NAP-1 induced chemotactic responses by T lymphocytes and basophils. Chemotactic potency (10(-8) M for an optimal response) was the same for all three cell types. However, NAP-1 caused a chemotactic response in excess of random migration of 7% or 16% of basophils (depending on the medium used) and only 9% of T lymphocytes, in contrast to 30% of neutrophils. This agonist was not chemotactic for partially purified normal human eosinophils. The symmetrical histogram obtained by flow cytometry of neutrophils equilibrated at 0 degree C with fluoresceinated NAP-1 indicates that all neutrophils bound the ligand. A dose-response curve plateau, and inhibition of binding of NAP-1-FITC by unlabeled ligand are evidence for saturable binding to receptors, estimated to be 7000 per cell. Our results suggest that, for induction of an acute inflammatory response, the quantitatively significant action of NAP-1 is on neutrophils.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2406341

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

1.  The role of CD18 in IL-8 induced dermal and synovial inflammation.

Authors:  M J Forrest; G J Eiermann; R Meurer; L A Walakovits; D E MacIntyre
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

2.  The human cytokine I-309 is a monocyte chemoattractant.

Authors:  M D Miller; M S Krangel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

3.  Neutrophil attractant protein-1-immunoglobulin G immune complexes and free anti-NAP-1 antibody in normal human serum.

Authors:  I Sylvester; T Yoshimura; M Sticherling; J M Schröder; M Ceska; P Peichl; E J Leonard
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

4.  Staphylococcal enterotoxin B-specific adhesion of murine splenic T cells to a human endothelial cell line.

Authors:  M Kita; K Eguchi; Y Kawabe; T Tsukada; K Migita; A Kawakami; N Matsuoka; S Nagataki
Journal:  Immunology       Date:  1996-07       Impact factor: 7.397

5.  Expression of adhesion molecules on granulocytes and monocytes from patients with asthma stimulated in vitro with interleukin-8 and monocyte chemotactic protein-1.

Authors:  E M Verdegaal; S T Zegveld; I Blokland; H Beekhuizen; W Bakker; L N Willems; R van Furth
Journal:  Inflammation       Date:  1998-04       Impact factor: 4.092

6.  Expression of CXCR1 (interleukin-8 receptor) in murine macrophages after staphylococcus aureus infection and its possible implication on intracellular survival correlating with cytokines and bacterial anti-oxidant enzymes.

Authors:  Biswadev Bishayi; Debasish Bandyopadhyay; Arnab Majhi; Rana Adhikary
Journal:  Inflammation       Date:  2015-04       Impact factor: 4.092

7.  Induction of interleukin (IL)-1beta and IL-8 mRNA expression in porcine macrophages by lipopolysaccharide from Serpulina hyodysenteriae.

Authors:  R E Sacco; S K Nibbelink; M J Baarsch; M P Murtaugh; M J Wannemuehler
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

8.  Inducible and constitutive in vitro neutrophil chemokine expression by mammary epithelial and myoepithelial cells.

Authors:  M R Barber; A G Pantschenko; L S Hinckley; T J Yang
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

9.  Transient rise in serum interleukin-8 concentration during acute myocardial infarction.

Authors:  Y Abe; M Kawakami; M Kuroki; T Yamamoto; M Fujii; H Kobayashi; T Yaginuma; A Kashii; M Saito; K Matsushima
Journal:  Br Heart J       Date:  1993-08

10.  SOLUBLE CD40 LIGAND IN DEMENTIA.

Authors:  B Giunta; K P Figueroa; T Town; J Tan
Journal:  Drugs Future       Date:  2009-04-01       Impact factor: 0.148

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.